Coronavirus Analysis

CoronaVirus_world_circle.jpg

In response to the urgent need for information about the coronavirus crisis, we are providing BioCentury’s coverage of the policy developments, scientific advances, and progress on countermeasures for free. Our team is updating this collection frequently as research develops.

• A comprehensive list of the new vaccines and therapeutics in development against the coronavirus can be found here.

CovidVaccinesTable_Landing.jpg

• The status of upcoming healthcare conferences can be found here.

ConferencesTableCovid19.jpg

• The status of upcoming regulatory meetings can be found here.

CovidVaccinesTable_Landing_Reg.jpg

Please send suggestions for additional coverage to: ncov2019@biocentury.com. We are developing stories about the discovery, testing and deployment of medical countermeasures, and the response of the biomedical community to the outbreak.

Get Daily COVID-19 & Biotech Industry Updates

New analysis is continuously added to our Coronavirus Collection. To get daily updates on the COVID-19 crisis and in-depth analysis of the entire biotech industry, request a trial subscription.

WEBINAR: LESSONS FROM WUHAN

The COVID-19 outbreak provides a unique challenge to U.S. healthcare professionals. Hear firsthand from doctors at Peking Union Medical College Hospital in China on effective measures for COVID-19 prevention, control and treatment, including real case studies on how to treat critically ill patients, and lessons learned from managing asymptomatic patients in China. Watch Webinar Now.

LATEST ARTICLES

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis

MAR 26, 2020 | 6:34 PM PDT

Global alliances among public, private and non-profit entities to counter COVID-19 continue to gather steam, with one of the latest alliances comprising over a dozen life sciences companies and the Gates Foundation

MAR 26, 2020 | 6:34 PM PDT

Nobody wants to waste already strained clinical resources and precious time with a scattershot approach to testing treatments for COVID-19

MAR 26, 2020 | 6:00 PM PDT

COVID-19 is no longer an approaching threat to clinical trials, now the concern for biotechs is how to manage their trials through the crisis

Mar 25, 2020 | 6:57 PM PDT

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy

Mar 25, 2020 | 6:22 PM PDT

A grand-scale behind-the-scenes effort by the pharmaceutical companies is under way to expedite the creation of therapies and vaccines to treat COVID-19

Mar 25, 2020 | 6:17 PM PDT

Jefferies is leading an initiative to raise as much as $1 billion to support HHS’s newly launched public-private partnership to build U.S.-based manufacturing capacity to rapidly produce hundreds of millions of prefilled medical-grade syringes

Mar 25, 2020 | 4:26 PM PDT

BIO's virtual summit on biotech's response to the COVID-19 pandemic generated a wish list of resources to support development of therapeutics, vaccines and diagnostics, with appeals to both government agencies and industry peers

Mar 25, 2020 | 4:24 PM PDT

Contrary to the situation for in-house preclinical research, preclinical CROs are largely open for business, according to a survey conducted by Science Exchange

Mar 25, 2020 | 3:57 PM PDT

Two days after receiving Orphan Drug designation for its COVID-19 therapeutic, Gilead has asked FDA to rescind the status and said it would waive “all benefits that accompany the designation”

Mar 25, 2020 | 12:32 PM PDT

A UCSF team has keyed in on more than five dozen compounds against nearly as many targets that could be repurposed to target the virus behind COVID-19

Mar 24, 2020 | 6:46 PM PDT

The overarching news was negative for biopharma Tuesday, with a fresh round of companies announcing trial delays. But Moderna offered a rare ray of light, hinting that its vaccine could be available sooner than many expected

Mar 24, 2020 | 6:41 PM PDT

New COVID-19 diagnostics were launched in Europe and the U.S. on Tuesday, while another company is speeding up development of an at-home PCR test

Mar 24, 2020 | 6:40 PM PDT

An international report released Tuesday provides a framework for what data COVID-19 vaccine developers should gather before moving into first-in-human studies

Mar 24, 2020 | 5:09 PM PDT

FDA Tuesday released guidance to help physicians provide convalescent plasma to COVID-19 patients on a compassionate use basis, outside of a clinical trial

Mar 24, 2020 | 2:03 PM PDT

Executives at biopharmas developing vaccines and therapeutics to treat COVID-19 provided updates on clinical timelines, the positive impact of regulatory collaboration and the need to dramatically expand manufacturing capacity in order to respond more quickly to future pandemics

Mar 24, 2020 | 11:18 AM PDT

As Gilead begins shifting its individual compassionate use authorizations for COVID-19 candidate remdesivir to broader expanded access programs, the antiviral was granted Orphan Drug designation Monday

Mar 23, 2020 | 6:06 PM PDT

Taking into consideration how social distancing and shelter in place edicts may make it difficult for patients to visit a lab, FDA released guidance Monday easing Risk Evaluation and Mitigation Strategy requirements

Mar 23, 2020 | 5:48 PM PDT

To inform public health measures to control the novel coronavirus outbreak, the U.K. has launched the COVID-19 Genomics UK Consortium to track viral spread and evolution via genome sequencing of COVID-19 samples

Mar 23, 2020 | 4:21 PM PDT

Politics, incompetence and disorganization got us into this mess. Science, solidarity and discipline can get us out of it.

Mar 23, 2020 | 12:25 PM PDT

HHS will fund a Phase II/III trial of Regeneron’s Kevzara, one of two IL-6 inhibitors that have entered pivotal studies in the past week to treat COVID-19

Mar 21, 2020 | 6:39 PM PDT

FDA granted Emergency Use Authorization to Cepheid’s Xpert Xpress SARS-CoV-2 test, the first point-of-care diagnostic for COVID-19

Mar 21, 2020 | 8:57 PM PDT

By solving the crystal structure of a SARS-CoV-2 protease, a University of Luebeck team was able to optimize a previously developed inhibitor for greater potency against the virus

Mar 20, 2020 | 5:29 PM PDT

Novartis and Teva join a growing list of pharmas with plans to ramp up supply of antimalarial drug hydroxychloroquine in the U.S. for COVID-19 despite sparse clinical data supporting the drug's efficacy in the indication

Mar 20, 2020 | 4:09 PM PDT

In response to the COVID-19 outbreak, FDA released guidance Friday encouraging companies and healthcare professionals to expand the use of remote monitoring technology to "help eliminate unnecessary patient contact and ease the burden on hospitals, other health care facilities, and health care professionals"

Mar 20, 2020 | 3:22 PM PDT

The phase three coronavirus stimulus bill that is expected to be signed into law next week is likely to include provisions that are intended to stimulate development of antibiotics, relax limits on carrying back net operating losses, mitigate drug shortages, and speed FDA review of medicines to treat and prevent COVID-19

Mar 20, 2020 | 2:31 PM PDT

It makes sense that CRISPR-Cas13 would enter the limelight during the COVID-19 crisis, given that the SARS-CoV-2 is an RNA virus, and this Cas enzyme targets RNA

Mar 20, 2020 | 1:39 PM PDT

Days after FDA outlined its thinking on adjustments to planned and ongoing clinical trials during the COVID-19 outbreak, EMA has followed suit with guidance that echoes many of the U.S. regulator's recommendations

Mar 20, 2020 | 12:15 PM PDT

NIH became the latest group to pare back its research due to the COVID-19 outbreak, following in the footsteps of multiple biopharmas that have paused preclinical and clinical programs this week

Mar 20, 2020 | 11:53 AM PDT

Diagnostics companies are continuing to step up to meet demand for expanded COVID-19 testing capabilities with a range of PCR- and antibody-based tests

Mar 20, 2020 | 11:45 AM PDT

An antibody-based assay from a Icahn School of Medicine at Mount Sinai could help epidemiologists better determine how and where COVID-19 is spreading, and how many people have been infected

Mar 19, 2020 | 5:51 PM PDT

A U.S. defense agency that specializes in turning science fantasies into realities jump-started technologies and nurtured companies that are now at the forefront of the response to the COVID-19 pandemic

Mar 19, 2020 | 4:45 PM PDT

Former FDA Commissioner Margaret Hamburg and FDA’s former Acting Chief Scientist Luciana Borio Thursday cautioned the agency to put science ahead of hope when responding to the COVID-19 pandemic

Mar 19, 2020 | 4:17 PM PDT

On Thursday, EMA's CHMP called on European researchers to pool resources and coordinate large, multi-country clinical trials of COVID-19 candidates in order to generate enough data for the European regulator to draw conclusions on efficacy

Mar 19, 2020 | 4:05 PM PDT

FDA should create task forces to facilitate the rapid development of point-of-care diagnostics, therapeutics and prophylactics for COVID-19, former FDA Commissioners Scott Gottlieb and Mark McClellan recommended in a working paper released Thursday

Mar 19, 2020 | 2:17 PM PDT

The start of a placebo-controlled Phase III trial of Genentech's Actemra to treat hospitalized patients with COVID-19 was one of several signs of progress Thursday among programs to treat or diagnose the disease

Mar 19, 2020 | 1:32 PM PDT

While repurposed agents for COVID-19 have largely focused on suppressing SARS-CoV-2, there is a strong case to be made for evaluating anti-inflammatory agents in patients with severe disease

Mar 18, 2020 | 6:11 PM PDT

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities

Mar 18, 2020 | 6:01 PM PDT

Industry is continuing to ramp up COVID-19 testing capacity to meet demand, as two diagnostics enter the U.S. market and HHS’s BARDA grants its fourth award for a COVID-19 assay

Mar 18, 2020 | 5:47 PM PDT

As the list of regulatory meetings affected by the COVID-19 outbreak grows, BioCentury is tracking the latest cancellations, reschedulings and options to attend virtually

Mar 18, 2020 | 5:44 PM PDT

WHO has launched an international master protocol to study the safety and effectiveness of drugs for treating patients hospitalized with COVID-19

Mar 18, 2020 | 2:18 PM PDT

BIO is hosting a two-day virtual summit with companies that are developing COVID-19 medical countermeasures, government officials and other stakeholders

Mar 17, 2020 | 6:59 PM PDT

Biopharma companies stretching from Asia to the U.S. and Europe Tuesday announced a flurry of deals, new initiatives and clinical updates for therapeutic and vaccine approaches to address the COVID-19 pandemic, including a partnership between BioNTech and Pfizer that sent the German mRNA player’s value up nearly $7 billion

Mar 17, 2020 | 5:55 PM PDT

The U.S. FDA Monday night announced new policies and Emergency Use Authorizations to expand COVID-19 test capacity

Mar 17, 2020 | 2:54 PM PDT

FDA grants EUA for Thermo Fisher’s diagnostic as Roche ships 400,000 COVID-19 tests

Mar 16, 2020 | 3:48 PM PDT

Ingmar Hoerr didn’t last long as CureVac’s newly re-appointed CEO. The German biotech said Monday that the company’s founder and chairman would take a temporary leave of absence for medical reasons unrelated to COVID-19

Mar 16, 2020 | 11:24 AM PDT

Biopharma executives rebuked Sen. Bernie Sanders (I-Vt.) for attacking them and the biopharmaceutical industry Sunday evening during a debate with former Vice President Joe Biden. Science, not politics, will defeat COVID-19, industry leaders told BioCentury

Mar 15, 2020 | 8:17 PM PDT

Pfizer is working with BioNTech to develop an mRNA-based COVID-19 vaccine, the pharma disclosed Friday while outlining its plan to fight COVID-19. The news sent BioNTech’s stock up $2.38 to $30.93 Friday

Mar 13, 2020 | 5:05 PM PDT

The race to create antibody-based treatments for COVID-19 gained momentum this week as two start-ups linked up with biopharma companies for mAb development expertise and manufacturing capacity

Mar 13, 2020 | 8:11 PM PDT

Results from clinical trials for COVID-19 could start to roll in any day, with antimalarials coming through first, according to BioCentury’s analysis of study completion dates in public databases

Mar 13, 2020 | 8:21 PM PDT

The U.S. government and industry took steps Friday to unlock COVID-19 testing capacity, including authorizing a commercial test, allowing New York to regulate tests conducted in the state, and funding development of two rapid diagnostics

Mar 13, 2020 | 7:53 AM PDT

EMA says its assessment and monitoring of medicines hasn’t been affected by the COVID-19 pandemic, even as the agency transitions to virtual meetings

Mar 12, 2020 | 2:25 PM PDT

Joe Biden Thursday blasted the Trump administration for the slow rollout of COVID-19 tests and Tony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases, acknowledged that the response has been “a failing”

Mar 12, 2020 | 2:19 PM PDT

FDA is postponing meetings, cancelling most travel and halting most foreign inspections as part of U.S. government-wide steps to contain the COVID-19 outbreak

Mar 11, 2020 | 1:32 PM PDT

The American Association for Cancer Research has postponed its April meeting, one of the largest medical meetings so far to be canceled due to the COVID-19 outbreak

Mar 10, 2020 | 4:06 PM PDT

The Bill & Melinda Gates Foundation, Wellcome Trust and Mastercard Tuesday announced that they will team up to invest up to $125 million to fund a COVID-19 Therapeutics Accelerator to speed the development of therapies for the coronavirus

Mar 10, 2020 | 3:05 PM PDT

The Coalition for Epidemic Preparedness Innovations (CEPI) will provide $4 million to Novavax to fund development of a COVID-19 vaccine program

Mar 10, 2020 | 1:10 PM PDT

Coalition for Epidemic Preparedness Innovations CEO Richard Hatchett says the organization urgently needs $2 billion to fund COVID-19 vaccine initiatives

Mar 9, 2020 | 5:18 PM PDT

COVID-19 testing capacity in the U.S. is ramping up slowly, but huge gaps remain between needs and capacity, and between government claims and reality

Mar 9, 2020 | 5:17 PM PDT

As the list of healthcare conferences affected by the COVID-19 outbreak grows, BioCentury is tracking the latest cancellations, reschedulings and options to attend virtually

Mar 9, 2020 | 12:46 PM PDT

The rush to make a vaccine for COVID-19 has raised concern that some candidate treatments could make infections worse

Mar 6, 2020 | 7:37 PM PST

In times of crisis, societies need competence, clarity and courage from their leaders -- qualities that have been in short supply during the COVID-19 outbreak

Mar 6, 2020 | 4:36 PM PST

Large scale virtual partnering in the age of COVID-19 will get its initial test at the first big European partnering event of the year, Bio-Europe Spring

Mar 6, 2020 | 2:38 PM PST

The U.S. Senate passed a COVID-19 spending package 96-1 Thursday. The bill (H.R. 6074) heads next to President Donald Trump, who is expected to sign it early next week

Mar 5, 2020 | 12:58 PM PST

A COVID-19 spending bill passed by the U.S. House of Representatives Wednesday would require that companies provide a “fair and reasonable” price for countermeasures sold to the government

Mar 4, 2020 | 5:25 PM PST

The biopharma industry is bringing additional modalities into the fight against COVID-19, with Vir and Alnylam developing an siRNA therapeutic while Takeda adds a plasma-based approach from COVID-19 survivors

Mar 4, 2020 | 3:56 PM PST

The Trump administration is sending mixed messages about pricing and government support for the development of COVID-19 vaccines

Mar 3, 2020 | 1:57 PM PST

In response to the COVID-19 outbreak, “India has restricted the export of 26 active pharmaceutical ingredients which represents about 10% of their export capacity,” FDA Commissioner Stephen Hahn said Tuesday. Testifying to the Senate Health, Education, Labor and Pensions Committee, Hahn said FDA is “working very closely to look at that list to assess how that will affect the medical supply chain”

Mar 3, 2020 | 10:42 AM PST

At a White House meeting Monday, biopharmaceutical executives presented a road map for a phased deployment of drugs and vaccines to combat COVID-19

Mar 2, 2020 | 9:09 PM PST

WHO has released a proposed master protocol for COVID-19 therapies and is developing a master protocol proposal for vaccines

Mar 2, 2020 | 3:13 PM PST

The first death in the U.S. attributed to COVID-19 was disclosed on Feb. 29

Feb 29, 2020 | 9:18 PM PST

CRISPR could see its first direct application to human health much earlier than expected as the COVID-19 outbreak accelerates development timelines for CRISPR-based diagnostics

Feb 28, 2020 | 7:45 PM PST

A WHO report on a Feb. 16-24 mission to China to assess the COVID-19 outbreak summarizes the situation on the ground, highlights countermeasure R&D initiatives, challenges and needs, and identifies critical knowledge gaps

Feb 28, 2020 | 3:26 PM PST

A look at the five Phase II and III clinical trials testing remdesivir to treat COVID-19 suggests the Gilead-sponsored trials may be least informative about efficacy

Feb 27, 2020 | 4:56 PM PST

The inability to hold face-to-face meetings as the coronavirus crisis deepens globally will have broad impacts across the biopharma industry on everything from dealmaking and fundraising to regulatory progress

Feb 27, 2020 | 3:55 PM PST

Qiagen said Wednesday it is seeking emergency FDA clearance for its coronavirus diagnostic

Feb 26, 2020 | 4:58 PM PST

In a global online forum Tuesday night, scientific leaders from companies developing vaccines, therapies and diagnostics to address the COVID-19 outbreak discussed opportunities for collaboration, highlighted challenges, and called for sustained global initiatives to create medical countermeasures to emerging infections

Feb 26, 2020 | 4:56 PM PST

NIH is kicking off the first U.S. clinical trials for COVID-19 with an adaptive trial of remdesivir, an antiviral therapeutic, and a Phase I trial of Moderna’s vaccine candidate

Feb 25, 2020 | 5:44 PM PST

As the response to the ongoing COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis

Feb 25, 2020 | 5:42 PM PST

The Trump administration has asked Congress for $1.8 billion in additional funding to address the COVID-19 outbreak, which would bring the total U.S. government commitment to $2.5 billion

Feb 25, 2020 | 7:01 AM PST

Vir and WuXi Biologics announced Tuesday a collaboration to develop and manufacture mAbs to treat COVID-19

Feb 25, 2020 | 6:32 AM PST

The Trump administration has asked Congress for $1.8 billion in additional funding to address the COVID-19 outbreak, which would bring the total U.S. government commitment to $2.5 billion

Feb 25, 2020 | 7:01 AM PST

The Singapore Ministry of Health has used an antibody test developed by the Duke-NUS Medical School to determine the source of a COVID-19 cluster

Feb 25, 2020 | 1:32 PM PST

With a call for proposals by the Innovative Medicines Initiative for COVID-19 development programs and a new vaccine development consortium led by a Denmark-based biotech, Europe is ramping up its response to the coronavirus outbreak

Feb 24, 2020 | 4:17 PM PST

Biotech indexes lost considerable ground during Monday’s trading session amid concerns of global supply chain disruptions due to the COVID-19 outbreak, although biotechs were generally spared the worst of the day’s losses, dipping by a slimmer percentage than indexes that measured the broader markets

Feb 24, 2020 | 2:58 PM PST

Clover, a Chengdu, China-based biopharmaceutical company, Monday announced a collaboration with GlaxoSmithKline to advance development of a COVID-19 vaccine candidate

Feb 24, 2020 | 12:38 PM PST

The COVID-19 crisis is mobilizing researchers to crank out therapeutic mAbs from a wide array of patient- and animal-based platforms, with the virus' spike protein emerging as the consensus target antigen

Feb 21, 2020 | 7:52 PM PST

The absence of pandemic or global health expertise at the White House National Security Council and on the Trump administration's Coronavirus Task Force is prompting Senate Democrats to raise concerns about the quality of advice provided to President Donald Trump, as well as the potential for political priorities to outweigh public health needs

Feb 20, 2020 | 3:26 PM PST

The biopharma industry and academics who are developing vaccines and therapies to prevent and treat COVID-19 pushed back Thursday against calls from members of Congress for price controls on medical countermeasures

Feb 20, 2020 | 4:09 PM PST

A UT Austin and NIH Vaccine Research Center team has uncovered the structure of the COVID-19 spike protein, which mediates viral entry into cells via membrane fusion. The findings, published in a Science paper Wednesday, could guide vaccine and mAb development for the new coronavirus

Feb 20, 2020 | 1:45 PM PST

Lockdowns and restrictions on movement imposed to control the COVID-19 outbreak could prevent HIV patients from getting access to lifesaving drugs, UNAIDS, a United Nations organization, warned Wednesday

Feb 19, 2020 | 2:40 PM PST

With support from HHS, Sanofi is adapting the platform behind its approved flu vaccine to develop a COVID-19 vaccine

Feb 18, 2020 | 5:09 PM PST

The coronavirus outbreak comes at a time when many major multinational pharmas are betting big on the China market for future growth

Feb 14, 2020 | 8:18 PM PST

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain

Feb 14, 2020 | 7:44 PM PST

Among the several dozen agents in clinical testing for COVID-19, in vitro data against the new coronavirus have only been reported for four, and they support the WHO’s prioritization of remdesivir from Gilead Sciences Inc. (NASDAQ:GILD)

Feb 14, 2020 | 7:17 PM PST

Just as China jumped to become AstraZeneca’s second-largest region by revenue, the U.K. pharma warned in its 2020 guidance that the COVID-19 outbreak may have a negative impact on revenues for at least the next few months

Feb 14, 2020 | 6:45 PM PST

Gilead is ramping up manufacturing of remdesivir, which is being tested as a potential treatment for COVID-19, the company told BioCentury Thursday

Feb 13, 2020 | 2:53 PM PST

Initial signals from two ongoing trials in China of Gilead’s of remdesivir to treat COVID-19 should be available in a few weeks, Marie-Paule Kieny said at a WHO press conference Wednesday

Feb 12, 2020 | 4:44 PM PST

Although Bio-Thera priced its Shanghai IPO Monday, the Guangzhou-based antibody company will likely prove to be the exception among biotechs planning to debut on the Shanghai and Hong Kong exchanges as Asian markets remain volatile and 2019-nCoV-related travel restrictions scuttle plans for roadshows

Feb 10, 2020 | 5:43 PM PST

The coronavirus outbreak in China has triggered a stark call to action across the international biopharma community to treat, diagnose and prevent the spread of the virus, but it has also revealed some cracks in China's infrastructure that have upended clinical and commercial operations in the region

Feb 7, 2020 | 9:00 PM PST

The number of groups that have announced vaccine programs against 2019-nCoV acute respiratory disease has jumped 50% from last week

Feb 7, 2020 | 8:06 PM PST

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response

Feb 7, 2020 | 7:13 PM PST

Insilico Medicine Inc. became the second AI company this week to contribute the speed of its platform to biopharma’s mass mobilization against the 2019-nCoV crisis

Feb 7, 2020 | 5:29 PM PST

The 2019-nCoV outbreak has not adversely affected supplies of drugs or active pharmaceutical ingredients to the U.S., FDA Commissioner Stephen Hahn said Friday

Feb 7, 2020 | 4:51 PM PST

Companies and government organizations have started large-scale deployment of diagnostics to diagnose and screen for the 2019-nCoV

Feb 6, 2020 | 2:13 PM PST

Gilead CEO Daniel O’Day said a patent application from two Chinese institutions for the use of the company’s unapproved antiviral remdesivir to treat the coronavirus “has no impact on what we’re going to do for global health”

Feb 5, 2020 | 5:35 PM PST

Regeneron and BenevolentAI unveiled a deal and a platform, respectively, on Tuesday that could yield therapies against 2019-nCoV that go beyond anti-inflammatory drugs for other viral infections

Feb 4, 2020 | 5:39 PM PST

Almost all major biopharma MNCs are conducting clinical trials in China that could face disruptions as the outbreak of 2019-nCoV acute respiratory disease continues to unfold

Feb 4, 2020 | 5:48 PM PST

FDA and EMA each unveiled measures Tuesday to combat the 2019-nCoV outbreak, with the U.S. agency issuing emergency use authorization for a diagnostic and its European counterpart activating its emerging health threats management plan

Feb 4, 2020 | 5:48 PM PST

Gilead’s remdesivir is the most promising candidate for treating 2019-nCoV acute respiratory disease, according to a draft report of WHO’s R&D Blueprint Clinical Trials expert group

Feb 4, 2020 | 4:56 PM PST

As China responds to the 2019-nCoV virus outbreak, executives of Chinese life sciences companies have pointed out that efforts to fight the virus could affect clinical trials across the nation, including postponement of new trials and continued enrollment of ongoing trials and increased usage of remote monitoring

Feb 4, 2020 | 12:53 PM PST

Nine clinical trials are under way to test therapeutic interventions for 2019-nCoV acute respiratory disease, according to ClinicalTrials.Gov and the Chinese Clinical Trial Register

Feb 3, 2020 | 5:34 PM PST

As Gilead plans a Chinese trial of remdesivir to treat the coronavirus, health authorities in Washington state reported that compassionate use of the nucleotide analog prodrug resolved almost all disease symptoms in one infected patient

Feb 3, 2020 | 5:03 PM PST

GlaxoSmithKline will provide its AS03 adjuvant technology to enhance 2019-nCoV vaccines that are being funded by the Coalition for Epidemic Preparedness Innovations, GSK and CEPI announced Sunday

Feb 2, 2020 | 8:41 PM PST

A tally of ongoing clinical trials in Wuhan, the city at the center of the coronavirus outbreak

Jan 31, 2020 | 5:56 PM PST

HHS Secretary Alex Azar Friday declared that 2019 Novel Coronavirus (2019-nCoV) poses a public health emergency

Jan 31, 2020 | 3:10 PM PST

Industry and academic centers are rushing to create new vaccines and therapeutics targeting coronavirus

Jan 30, 2020 | 5:22 PM PST

Ascletis is seeking the approval of China’s NMPA for emergency use of its protease inhibitors to treat 2019-nCoV coronavirus after the government released guidelines suggesting AbbVie’s Kaletra as a treatment for the virus

Jan 29, 2020 | 6:04 PM PST

AbCellera Biologics Inc. has started a program to discover mAbs as potential treatments for patients infected with the 2019-nCoV that was first identified in Wuhan, China, the company’s CEO, Carl Hansen, told BioCentury

Jan 28, 2020 | 1:37 PM PST

Two more companies have announced that they are developing vaccines to protect against the 2019-nCoV outbreak that was first detected in Wuhan, China, bringing the total number of vaccine development programs to at least 10

Jan 27, 2020 | 3:20 PM PST

The coronavirus outbreak is creating a testbed for new vaccine and therapeutic technologies

Jan 24, 2020 | 8:02 PM PST

The rapid sharing of the genetic sequence of the 2019 novel coronavirus (2019-nCoV), first identified in Wuhan, China, has sparked an extraordinary response from biopharma companies, academic researchers and governments

Jan 23, 2020 | 2:04 PM PST

At least four groups have started to develop vaccines to protect against the 2019 Novel Coronavirus (2019-nCoV) that was first detected in Wuhan, China

Jan 21, 2020 | 5:02 PM PST